{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T05:10:17Z","timestamp":1733289017526,"version":"3.30.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,2]]},"DOI":"10.7759\/cureus.75000","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T05:13:26Z","timestamp":1733202806000},"source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Cetuximab Leading to a Complete Pathologic Response in Locally Advanced Lip Squamous Cell Carcinoma"],"prefix":"10.7759","author":[{"given":"Ruba","family":"Alchaikh Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Gafarzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiva","family":"Salmasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M","family":"Hyams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin A","family":"Dasanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adoms.2022.100276","article-title":"Lip cancer prevalence, epidemiology, diagnosis, and management: a review of the literature","volume":"6","author":"Alhabbab R","year":"2022","unstructured":"Alhabbab R, Johar R. Lip cancer prevalence, epidemiology, diagnosis, and management: a review of the literature. Adv Oral Maxillofac Surg. 2022, 6:100276. 10.1016\/j.adoms.2022.100276","journal-title":"Adv Oral Maxillofac Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00826-3","article-title":"Neoadjuvant therapy for non-melanoma skin cancer: updated therapeutic approaches for basal, squamous, and Merkel cell carcinoma","volume":"22","author":"Zelin E","year":"2021","unstructured":"Zelin E, Zalaudek I, Agozzino M, et al.. Neoadjuvant therapy for non-melanoma skin cancer: updated therapeutic approaches for basal, squamous, and Merkel cell carcinoma. Curr Treat Options Oncol. 2021, 22:35. 10.1007\/s11864-021-00826-3","journal-title":"Curr Treat Options Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00383","article-title":"Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma","volume":"9","author":"Taberna M","year":"2019","unstructured":"Taberna M, Oliva M, Mes\u00eda R. Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma. Front Oncol. 2019, 9:383. 10.3389\/fonc.2019.00383","journal-title":"Front Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0799-x","article-title":"Changes in the 8th edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: rationale and implications","volume":"21","author":"Zanoni DK","year":"2019","unstructured":"Zanoni DK, Patel SG, Shah JP. Changes in the 8th edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: rationale and implications. Curr Oncol Rep. 2019, 21:52. 10.1007\/s11912-019-0799-x","journal-title":"Curr Oncol Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26646","article-title":"Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score","volume":"118","author":"Extermann M","year":"2012","unstructured":"Extermann M, Boler I, Reich RR, et al.. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012, 118:3377-86. 10.1002\/cncr.26646","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_435_18","article-title":"Dermoscopic features of lower lip squamous cell carcinoma: a descriptive study","volume":"10","author":"Elmas \u00d6F","year":"2019","unstructured":"Elmas \u00d6F, Metin MS, Kilit\u00e7i A. Dermoscopic features of lower lip squamous cell carcinoma: a descriptive study. Indian Dermatol Online J. 2019, 10:536-41. 10.4103\/idoj.IDOJ_435_18","journal-title":"Indian Dermatol Online J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2016.3455","article-title":"Epidemiology of squamous cell carcinoma of the lip in the United States a population-based cohort analysis","volume":"142","author":"Han AY","year":"2016","unstructured":"Han AY, Kuan EC, Mallen-St Clair J, Alonso JE, Arshi A, St John MA. Epidemiology of squamous cell carcinoma of the lip in the United States a population-based cohort analysis. JAMA Otolaryngol Head Neck Surg. 2016, 142:1216-23. 10.1001\/jamaoto.2016.3455","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0792","article-title":"Association of nodal metastasis and mortality with vermilion vs cutaneous lip location in cutaneous squamous cell carcinoma of the lip","volume":"154","author":"Wang DM","year":"2018","unstructured":"Wang DM, Kraft S, Rohani P, et al.. Association of nodal metastasis and mortality with vermilion vs cutaneous lip location in cutaneous squamous cell carcinoma of the lip. JAMA Dermatol. 2018, 154:701-7. 10.1001\/jamadermatol.2018.0792","journal-title":"JAMA Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13594","article-title":"Treatment outcomes of squamous cell carcinoma of the lip: a retrospective study","volume":"25","author":"Babu G","year":"2023","unstructured":"Babu G, Ravikumar R, Rafi M, et al.. Treatment outcomes of squamous cell carcinoma of the lip: a retrospective study. Oncol Lett. 2023, 25:8. 10.3892\/ol.2022.13594","journal-title":"Oncol Lett"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235494","article-title":"Neoadjuvant Approaches to Non-Melanoma Skin Cancer","volume":"15","author":"Wilde DC","year":"2023","unstructured":"Wilde DC, Glaun ME, Wong MK, Gross ND. Neoadjuvant Approaches to Non-Melanoma Skin Cancer. Cancers (Basel). 2023, 15:23. 10.3390\/cancers15235494","journal-title":"Cancers (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0585","article-title":"Pilot Phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck","volume":"27","author":"Ferrarotto R","year":"2021","unstructured":"Ferrarotto R, Amit M, Nagarajan P, et al.. Pilot Phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2021, 27:4557-65. 10.1158\/1078-0432.CCR-21-0585","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma","volume":"387","author":"Gross ND","year":"2022","unstructured":"Gross ND, Miller DM, Khushalani NI, et al.. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022, 387:1557-68. 10.1056\/NEJMoa2209813","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner JA","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, et al.. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 354:567-78. 10.1056\/NEJMoa053422","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna H","year":"2019","unstructured":"Mehanna H, Robinson M, Hartley A, et al.. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019, 393:51-60. 10.1016\/S0140-6736(18)32752-1","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison ML","year":"2019","unstructured":"Gillison ML, Trotti AM, Harris J, et al.. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019, 393:40-50. 10.1016\/S0140-6736(18)32779-X","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13741","article-title":"Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas","volume":"173","author":"Reigneau M","year":"2015","unstructured":"Reigneau M, Robert C, Routier E, Mamelle G, Moya-Plana A, Tomasic G, Mateus C. Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. Br J Dermatol. 2015, 173:527-34. 10.1111\/bjd.13741","journal-title":"Br J Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0298","article-title":"Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy","volume":"16","author":"Pinto C","year":"2011","unstructured":"Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, Maiello E. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. 2011, 16:228-38. 10.1634\/theoncologist.2010-0298","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/318761-neoadjuvant-cetuximab-leading-to-a-complete-pathologic-response-in-locally-advanced-lip-squamous-cell-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T05:13:28Z","timestamp":1733202808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/318761-neoadjuvant-cetuximab-leading-to-a-complete-pathologic-response-in-locally-advanced-lip-squamous-cell-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.75000","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,2]]}}}